![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1351107
¼¼°èÀÇ ÀÓ»ó½ÃÇè¿ë Æ÷Àå ½ÃÀå ¿¹Ãø(-2030³â) : ºÎ¹®º° ¹× Áö¿ªº° ºÐ¼®Clinical Trial Packaging Market Forecasts to 2030 - Global Analysis By Product Type, Clinical Trial Type, Material, End User and By Geography |
Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ÀÓ»ó½ÃÇè¿ë Æ÷Àå ½ÃÀåÀº 2023³â 30¾ï 4,000¸¸ ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È 12.7%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2030³â 70¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÓ»ó½ÃÇè Á¦Ç°Àº ÀÓ»ó½ÃÇè¿ë Æ÷Àå ¼Ö·ç¼ÇÀ» »ç¿ëÇÏ¿© Æ÷Àå, º¸°ü, º¸È£ ¹× ¿î¼ÛµË´Ï´Ù. ÀÓ»ó½ÃÇèÀº ÀǾàǰÀÇ È¿´ÉÀ» Æò°¡ÇÏ°í ´Ù¾çÇÑ ÀǾàǰÀÇ ÃÖÀû ¿ë·®À» °áÁ¤Çϱâ À§ÇØ ½Ç½ÃµË´Ï´Ù. ÀÓ»ó½ÃÇè¿¡´Â ÁÖ»ç±â, º´, ¹°Áý, Æ©ºê, ¾ÚÇÃ, ¹ÙÀ̾Ë, ¹é, ÆÄ¿ìÄ¡, ºÀÁö µî ´Ù¾çÇÑ Á¦Ç°ÀÌ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ Ç¥ÁØ Æ÷ÀåÀº ƯÈ÷ ¹Î°¨ÇÑ ¾à¹°ÀÇ °æ¿ì ÀÓ»ó½ÃÇè °á°ú¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ ÀÌ·¯ÇÑ Á¦Ç°¿¡´Â Ư¼ö Æ÷ÀåÀÌ ÇÊ¿äÇÕ´Ï´Ù.
CPSC¿¡ µû¸£¸é, ¿ì¸®°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀº °³º° ȯÀÚÀÇ ¾à¹° Á¶Á¦¸¦ Æò°¡ÇÒ ¶§ ÀÇ»çÀÇ °³ÀÔÀ» Æ÷ÇÔÇØ¾ß ÇÕ´Ï´Ù.
´ÜŬ·ÐÇ×ü, ¼¼Æ÷Ä¡·áÁ¦, À¯ÀüÀÚÄ¡·áÁ¦¿Í °°Àº »ý¹°ÇÐÀû Á¦Á¦ÀÇ °³¹ß·Î ÀÓ»ó½ÃÇè ºÐ¾ß´Â Å« º¯È¸¦ °Þ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü Ä¡·áÁ¦´Â ¾ÈÁ¤¼º°ú ¹«°á¼ºÀ» À¯ÁöÇϱâ À§ÇØ Æ¯¼öÇÑ Æ÷Àå ¼Ö·ç¼ÇÀ» ÇÊ¿ä·Î ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ ȯÀÚ¿¡°Ô Ä¡·á¸¦ Àû¿ëÇÏ´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á·Î ÀÎÇØ Æ÷Àå ¿ä±¸»çÇ×ÀÌ ´õ¿í ´Ù¾çÇØÁö°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ¿ë·®, Á¦Çü ¹× Åõ¿© ¹æ¹ý¿¡ ´ëÀÀÇϱâ À§ÇØ Æ¯¼öÇÑ Æ÷Àå ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù.
ÀÓ»ó½ÃÇè¿ë Æ÷Àå ½ÃÀå¿¡ Å« À庮ÀÌ µÇ°í ÀÖ´Â °ÍÀº ȯ°æ Áö¼Ó°¡´É¼º¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ȯ°æ ¿µÇâÀ» ÁÙÀ̱â À§ÇØ ±â¾÷µéÀº ȯ°æ Ä£ÈÀûÀÎ Æ÷Àå Àü·«À» äÅÃÇØ¾ß ÇÑ´Ù´Â ¾Ð·ÂÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Ä£È¯°æ ÆÐŰ¡ ¿É¼ÇÀ» °³¹ß ¹× ±¸ÇöÇÏ´Â µ¥ µå´Â ºñ¿ëÀÌ ³ôÀ» ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°è ȯ°æ ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â °æ¿ì¿¡µµ ¼öÀÍ·ü°ú ¿î¿µ ºñ¿ë¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
ÀÓ»ó½ÃÇè¿ë Æ÷ÀåÀº µðÁöÅÐ ±â¼úÀ» µµÀÔÇÔÀ¸·Î½á Å« ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¾ÈÀüÇÑ µ¥ÀÌÅÍ °øÀ¯¸¦ À§ÇÑ ºí·ÏüÀÎ, ÃßÀû¼º Çâ»óÀ» À§ÇÑ QR ÄÚµå, ½Ç½Ã°£ ¸ð´ÏÅ͸µÀÌ °¡´ÉÇÑ IoT Áö¿ø ÆÐŰ¡°ú °°Àº Çõ½ÅÀº ÆÐŰ¡ »ê¾÷¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ±â¼úÀ» Ȱ¿ëÇÏ´Â ÆÐŰ¡ ȸ»ç´Â ¿À·ù¸¦ ÁÙÀ̰í È¿À²¼ºÀ» ³ô¿© ÀÓ»ó½ÃÇè °ø±Þ¸ÁÀ» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÓ»ó½ÃÇè¿ë Æ÷Àå ½ÃÀåÀº ÇÃ¶ó½ºÆ½, ±Ý¼Ó, Ư¼ö Æ÷Àå ºÎǰ°ú °°Àº ¿øÀÚÀç °¡°ÝÀÇ º¯µ¿À¸·Î ÀÎÇØ Ç×»ó À§ÇùÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ±Þ°ÝÇÑ °¡°Ý »ó½ÂÀº ÀÌÀÍ·üÀ» ³·Ãß°í Àüü ÆÐŰ¡ ¼Ö·ç¼ÇÀÇ ºñ¿ë È¿À²¼º¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¶ÇÇÑ ±â¾÷Àº ÀÌ·¯ÇÑ À§ÇùÀ» ÁÙÀ̱â À§ÇØ È¿°úÀûÀÎ Á¶´Þ Àü·«À» ¼ö¸³ÇÏ°í ¿øÀÚÀç ½ÃÀåÀ» ¸é¹ÐÈ÷ ¸ð´ÏÅ͸µÇØ¾ß ÇÕ´Ï´Ù. À̸¦ ÅëÇØ ºñ¿ë º¯µ¿À» ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÓ»ó½ÃÇè¿ë Æ÷Àå ½ÃÀåÀº COVID-19ÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ Å« ¿µÇâÀ» ¹Þ¾Ò½À´Ï´Ù. ¼¼°è °ø±Þ¸Á°ú Á¦Á¶ ÀýÂ÷ÀÇ È¥¶õÀ¸·Î ÀÎÇØ ÃÊ±â Æ÷Àå °ø±ÞÀÇ Áö¿¬°ú ºÎÁ·À¸·Î ÀÎÇØ ÀÓ»ó½ÃÇèÀÇ Àû½Ã ¿Ï·á¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¶ÇÇÑ ¾ö°ÝÇÑ ºÀ¼â ÀýÂ÷¿Í ¿©Çà Á¦ÇÑÀ¸·Î ÀÎÇØ ÀÓ»ó½ÃÇè Àç·áÀÇ À¯ÅëÀÌ ¹æÇØ¹Þ¾Æ ¹°·ù¿¡ ¾î·Á¿òÀ» °Þ¾ú½À´Ï´Ù. ±×·¯³ª Àü¿°º´Àº ¶ÇÇÑ ¾÷°è Àü¹ÝÀÇ µðÁöÅÐÈ ³ë·ÂÀ» °¡¼ÓÈÇÏ¿© ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ½º¸¶Æ® Æ÷Àå ±â¼ú äÅÃÀ¸·Î À̾îÁ³½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È º´ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿¡ Æ÷ÀåµÈ ÀǾàǰÀº Á¤Á¦, ¾×ü, Á¤Á¦ ¹× ĸ½¶°ú °°Àº °íÇüÁ¦ µî ´Ù¾çÇÑ Á¾·ùÀÇ ÀǾàǰÀÌ º´¿¡ Æ÷ÀåµÇ¾î ÀÖ½À´Ï´Ù. º´Àº ÀûÀÀ·ÂÀÌ ¶Ù¾î³ª°í »ç¿ëÇϱ⠽¬¿ì¸ç ´Ù¾çÇÑ º¸°ü ¹× Á¶Á¦ ¿ä±¸ »çÇ×À» ÃæÁ·½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´Àº ´Ù¾çÇÑ Å©±â¿Í ÀçÁú·Î Á¦°øµÇ¹Ç·Î Á¦¾à ȸ»ç´Â Á¦Ç°ÀÇ Æ¯Á¤ ¿ä±¸ »çÇ×À» ÃæÁ·ÇÏ´Â Æ÷Àå ¿É¼ÇÀ» ¼±ÅÃÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÓ»ó½ÃÇè Æ÷Àå ½ÃÀå¿¡¼ ÀÓ»ó ¿¬±¸ ±â°ü ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. CRO´Â ȯÀÚ ¸ðÁý, µ¥ÀÌÅÍ °ü¸®, ¹ý·ü Áؼö µî ÀÓ»ó ¿¬±¸ ¾÷¹«ÀÇ ´ëºÎºÐÀ» °ü¸®Çϸç, Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ ÀÌÀÍÀ» À§ÇØ ÀÓ»ó½ÃÇè ¼öÇà¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ, Á¦¾à»ç¿Í »ý¸í°øÇÐ ±â¾÷µéÀº ºñ¿ë Àý°¨°ú Àü¹®¼ºÀ» ÀÌÀ¯·Î ÀÓ»ó½ÃÇè ¾÷¹«¸¦ CRO¿¡ À§Å¹ÇÏ´Â °æ¿ì°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â CROÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè ¼öÀÇ Áõ°¡¿Í ÀÓ»ó½ÃÇè¿ë Æ÷Àå ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ CRO ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
ÀÓ»ó½ÃÇè¿ë Æ÷ÀåÀÇ °¡Àå Å« ½ÃÀå Á¡À¯À²Àº ºÏ¹Ì, ƯÈ÷ ¹Ì±¹À̾ú½À´Ï´Ù. ºÏ¹ÌÀÇ ¿ìÀ§´Â ¹ø¼ºÇÏ´Â »ý¸í°øÇÐ ¹× Á¦¾à »ê¾÷, ±¤¹üÀ§ÇÑ ÀÓ»ó½ÃÇè Ȱµ¿, È®¸³µÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀº Á¤±³ÇÑ ÀÇ·á ½Ã½ºÅÛ°ú Çõ½Å¿¡ ´ëÇÑ Çå½ÅÀ¸·Î ÀÓ»ó½ÃÇè¿ë Æ÷Àå ºÐ¾ß¿¡¼ ¼¼°è ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù.
ÀÓ»ó½ÃÇè¿ë Æ÷Àå ½ÃÀå¿¡¼´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ȯÀÚ Àα¸°¡ ¸¹°í ´Ù¾çÇϸç, Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷ÀÌ ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾Æ ÀϺΠ±¹°¡´Â Àú·ÅÇÑ °¡°ÝÀ¸·Î Á¦Á¶ ¹× Æ÷ÀåÀÌ °¡´ÉÇØ ÀÓ»ó½ÃÇè¿ë Æ÷Àå ¼ºñ½º °ø±Þó·Î¼ ¾Æ½Ã¾Æ Áö¿ªÀÇ ¸Å·ÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Clinical Trial Packaging Market is accounted for $3.04 billion in 2023 and is expected to reach $7.03 billion by 2030 growing at a CAGR of 12.7% during the forecast period. Clinical trial products are packaged, stored, protected, and transported using clinical trial packaging solutions. Clinical trials are conducted to evaluate a drug's effectiveness and determine the best dose for various pharmaceutical formulations. Clinical trials involve the use of a wide range of products, including syringes, bottles, blisters, tubes, ampoules and vials, bags and pouches, and sachets. Moreover, these products require special packaging because standard packaging has a negative impact on clinical trial outcomes, particularly for highly sensitive drugs.
According to CPSC, the options available to us must incorporate physician involvement in assessing dispensation of drug to individual patients.
With the development of biologics like monoclonal antibodies, cell therapies, and gene therapies, the field of clinical trials has undergone significant change. To maintain their stability and integrity, these cutting-edge therapies frequently need specialized packaging solutions. Additionally, the packaging requirements have become even more varied as a result of personalized medicine, which adapts treatments to specific patients. To accommodate various dosages, formulations, and administration techniques, specialized packaging solutions are required.
A significant barrier to the market for clinical trial packaging is the increasing focus on environmental sustainability. In order to lessen their impact on the environment, businesses are under increasing pressure to adopt eco-friendly packaging strategies. Furthermore, the cost of developing and implementing these environmentally friendly packaging options may be higher, which will have an impact on profit margins and operating expenses even though they are in line with global environmental goals.
Clinical trial packaging offers significant opportunities when digital technologies are incorporated. Innovations like blockchain for secure data sharing, QR codes for improved traceability, and IoT-enabled packaging with real-time monitoring capabilities are revolutionizing the packaging industry. Moreover, packaging companies that use these technologies can improve supply chains for clinical trials by doing so while lowering errors and increasing efficiency.
The clinical trial packaging market is constantly threatened by changes in the price of raw materials like plastics, metals, and specialty packaging components. Sudden price increases can reduce profit margins, which affects how cost-effective packaging solutions are overall. Additionally, companies need to establish effective procurement strategies and closely monitor the markets for raw materials to reduce this threat. This will help them control cost fluctuations.
The clinical trial packaging market was significantly affected by the COVID-19 pandemic. Initial delays and shortages in packaging supplies had an impact on the timely completion of clinical trials due to disruptions in global supply chains and manufacturing procedures. Furthermore, the distribution of clinical trial materials was hampered by strict lockdown procedures and travel restrictions, creating logistical difficulties. But the pandemic also sped up industry wide efforts to transform digitally, leading to the adoption of remote monitoring and smart packaging technologies.
During the forecast period, it is anticipated that the bottle segment will hold the largest share. Many different types of medications, including oral medications, liquids, and even solid dosage forms like tablets and capsules, are packaged in bottles. They are adaptable, simple to use, and can accommodate various storage and dispensing requirements. Additionally, bottles are available in a range of sizes and materials, so pharmaceutical companies can select packaging options that meet the particular needs of their products.
In the market for clinical trial packaging, the clinical research organization segment is growing at the highest CAGR during the anticipated period. For the benefit of pharmaceutical and biotechnology companies, CROs are essential in carrying out clinical trials. They manage a sizable portion of clinical research tasks, such as patient recruitment, data management, and legal compliance. Furthermore, Pharmaceutical and biotechnology companies are increasingly outsourcing clinical trial activities to CROs due to cost savings and specialized knowledge, which is fueling these companies' remarkable growth. The growing number of clinical trials and the increase in demand for clinical trial packaging services also contributed to the growth of the CRO segment.
The largest market share for clinical trial packaging was held by North America, particularly the United States. North America's dominance can be attributed to its thriving biotechnology and pharmaceutical industries, extensive clinical trial activities, well-established regulatory framework, and substantial investments in research and development. Moreover, this region leads the world in clinical trial packaging due to its sophisticated healthcare system and commitment to innovation.
In the market for clinical trial packaging, the Asia-Pacific region is expected to have the highest CAGR. The region's large and diverse patient population and the burgeoning pharmaceutical and biotechnology industries were the main drivers of this growth, as were raising investments in healthcare infrastructure. Additionally, some Asian nation's affordable manufacturing and packaging options added to the region's appeal as a source of clinical trial packaging services.
Some of the key players in Clinical Trial Packaging market include: PCI Pharma Services, Schreiner MediPharm, Berry Global, Inc., 3M Company, Nupharm Group , Catalent, Inc. , Sharp Clinical Services, Inc. , Korber Medipak Systems AG, Parexel International Corporation , Alcami Corporation, Inc., Reed-Lane, Inc., Aphena Pharma Solutions, Symbiosis Pharmaceutical Services, Carton Service, Inc., Piramal Pharma Solutions , Thermo Fisher Scientific Inc., Xerimis Inc., NextPharma Technologies Holding Limited, WestRock Company, Sentry BioPharma Services, Inc. and Yourway Transport Inc.
In May 2023, 3M today announced it has entered into agreements to sell certain assets associated with its dental local anesthetic portfolio, based in Seefeld, Germany, to Pierrel S.p.A., a global provider of services for the pharmaceutical industry, for a purchase price of $70 million, subject to closing and other adjustments.
In May 2023, Schreiner MediPharm has introduced a counterfeit and tampering protection solution whose void effect makes it exceedingly difficult for counterfeiters to successfully reuse original packaging. The company's tailored Void-Labels make previously covert messages readily visible upon peeling, making a package's first opening clearly and irreversibly apparent.
In April 2023, PCI Pharma Services (PCI), a leading global contract development and manufacturing organization announced that three new state-of-the-arts automated sterile fill-finish machines at its San Diego and Melbourne facilities are now fully operational. The innovative machinery from Cytiva can be used to fill various sterile medications into vials and syringes for small-to-mid scale client needs.